A follow‐up study of immunotherapy‐treated birch‐allergic patients: effect on the expression of chemokines in the nasal mucosa

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical and Experimental Allergy

• Publication date

  2008-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1365-2222.2008.03005.xPMID 18691293
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• T lymphocytes expressing CCR3 are increased in allergic rhinitis compared with non‐allergic controls and following allergen immunotherapy

  2007cited by this paper
• Increased expression of lipoxygenase enzymes during pollen season in nasal biopsies of pollen‐allergic patients

  2006cited by this paper
• Effect of inhaled corticosteroid on an immunoreactive thymus and activation‐regulated chemokine expression in the bronchial biopsies from asthmatics

  2005cited by this paper
• IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy.

  2005cited by this paper
• Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis.

  2004cited by this paper
• The effect of specific immunotherapy on the expression of costimulatory molecules in late phase reaction of the skin in allergic patients

  2004cited by this paper
• Eosinophil degranulation status in allergic rhinitis: observations before and during seasonal allergen exposure

  2004cited by this paper
• Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double‐blind, randomized, placebo‐controlled trial

  2003cited by this paper
• Cc‐chemokine eotaxin as a marker of efficacy of specific immunotherapy in patients with intermittent IgE‐mediated allergic rhinoconjunctivitis

  2003cited by this paper
• Plasma TARC concentration may be a useful marker for asthmatic exacerbation in children

  2003cited by this paper
• Eotaxin and CCR3 are up‐regulated in exacerbations of chronic bronchitis

  2002cited by this paper
• Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy.

  2002cited by this paper
• CCR4 in human allergen‐induced late responses in the skin and lung

  2002cited by this paper
• The effect of omalizumab on nasal allergic inflammation.

  2002cited by this paper
• Plasma concentration of thymus and activation-regulated chemokine is elevated in childhood asthma.

  2002cited by this paper
• Eotaxin but not MCP−3 induces eosinophil influx into nasal fluid in allergic patients

  2002cited by this paper
• Long‐term efficacy of preseasonal grass pollen immunotherapy in children

  2002cited by this paper
• The kinetics of allergen-induced eotaxin level in nasal lavage fluid: its key role in eosinophil recruitment in nasal mucosa.

  2001cited by this paper
• Expression of C–C chemokine TARC in human nasal mucosa and its regulation by cytokines

  2001cited by this paper
• Upregulation of nasal mucosal eotaxin in patients with allergic rhinitis during grass pollen season: effect of a local glucocorticoid

  2000cited by this paper
• Allergen immunotherapy: does it work and, if so, how and for how long?

  2000cited by this paper
• Tryptase-chymase double-positive human mast cells express the eotaxin receptor CCR3 and are attracted by CCR3-binding chemokines.

  1999cited by this paper
• C-C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other C-C chemokines (mono

  1999cited by this paper
• The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells

  1999cited by this paper
• Grass pollen immunotherapy decreases the number of mast cells in the skin

  1999cited by this paper
• Early modifications of chemokine production and mRNA expression during rush venom immunotherapy.

  1998cited by this paper
• Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper.

  1998cited by this paper
• Allergen immunotherapy: therapeutic vaccines for allergic diseases

  1998cited by this paper
• RANTES induces nasal mucosal inflammation rich in eosinophils, basophils, and lymphocytes in vivo.

  1998cited by this paper
• Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (Th1s) and Th2s

  1998cited by this paper
• Eotaxin mRNA and protein expression in chronic sinusitis and allergen-induced nasal responses in seasonal allergic rhinitis.

  1997cited by this paper
• RANTES in human allergen-induced rhinitis: cellular source and relation to tissue eosinophilia.

  1997cited by this paper
• Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long‐term (6‐year) follow‐up

  1997cited by this paper
• Cutaneous injection of RANTES causes eosinophil recruitment: comparison of nonallergic and allergic human subjects.

  1997cited by this paper
• Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma.

  1996cited by this paper
• Immunotherapy suppresses the production of monocyte chemotactic and activating factor and augments the production of IL-8 in children with asthma.

  1996cited by this paper
• Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy.

  1995cited by this paper
• Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses.

  1993cited by this paper
• Dynamics of mast cells in the nasal mucosa of patients with allergic rhinitis and non‐allergic controls: a biopsy study

  1992cited by this paper
• Immunohistology of the nasal mucosa in seasonal allergic rhinitis: increases in activated eosinophils and epithelial mast cells.

  1992cited by this paper
• Immunotherapy with cat- and dog-dander extracts

  1991cited by this paper
• Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs.

  1991cited by this paper
• Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment.

  1991cited by this paper
• Changes in nasal metachromatic cells during allergen immunotherapy

  1991cited by this paper
• Allergen-induced changes in the nasal mucous membrane in seasonal allergic rhinitis: effect of nedocromil sodium.

  1990cited by this paper
• Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES

  1990cited by this paper
• Immunotherapy with partially purified and standardized tree pollen extracts

  1988cited by this paper

• A Review on Novel Therapeutic Modalities and Evidence-based Drug Treatments Against Allergic Rhinitis.

  2024cites this paper
• Pathogenesis and Key Cells in Allergic Rhinitis

  2024cites this paper
• Mechanisms of Allergen Immunotherapy and Potential Biomarkers for Clinical Evaluation

  2023cites this paper
• Allergic Rhinitis: A Clinical and Pathophysiological Overview

  2022cites this paper
• Passive Prophylactic Administration with a Single Dose of Anti–Fel d 1 Monoclonal Antibodies REGN1908–1909 in Cat Allergen–induced Allergic Rhinitis: A Randomized, Double-Blind, Placebo-controlled Clinical Trial

  2021cites this paper
• RNAS LONGOS NÃO CODIFICADORES E RINITE: UMA REVISÃO

  2021cites this paper
• The build-up phase outcome of subcutaneous immunotherapy for pediatric allergic asthma: A retrospective cohort study from Surabaya, Indonesia

  2019cites this paper
• Allergic rhinitis is associated with complex alterations in high-density lipoprotein composition and function.

  2019cites this paper
• Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper

  2017cites this paper
• A novel mannoside-glycocluster adjuvant: Compared in vitro to CpG ODN and MPL and tested in vivo in mouse asthma model.

  2016cites this paper
• SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis.

  2016cites this paper
• Specific allergen immunotherapy: effect on IgE, IgG4 and chemokines in patients with allergic rhinitis

  2016cites this paper
• Pathogenesis of rhinitis

  2016cites this paper
• Effects of venom immunotherapy on serum level of CCL5/RANTES in patients with Hymenoptera venom allergy

  2015cites this paper
• Airway inflammatory markers in asthma and rhinitis : microRNA, nasal nitric oxide and proteome analysis

  2014cites this paper
• Under the skin or under the tongue: differences and similarities in mechanisms of sublingual and subcutaneous immunotherapy.

  2013cites this paper
• Mechanisms of allergen-specific immunotherapy and novel ways for vaccine development.

  2013cites this paper
• Therapies for allergic inflammation: refining strategies to induce tolerance

  2012cites this paper
• Serum TARC and CTACK concentrations in children with atopic dermatitis, allergic asthma, and urticaria

  2012cites this paper
• 3-years' long-term effect of subcutaneous immunotherapy (SCIT) with a high-dose hypoallergenic 6-grass pollen preparation in adults.

  2012influential citation
• Nasal lavage CCL24 levels correlate with eosinophils trafficking and symptoms in chronic sino-nasal eosinophilic inflammation.

  2011cites this paper
• Pathophysiology of allergic and nonallergic rhinitis.

  2011cites this paper
• Mechanisms of subcutaneous allergen immunotherapy.

  2011cites this paper
• Developments in the field of allergy in 2008 through the eyes of Clinical & Experimental Allergy

  2009cites this paper
• Specific immunotherapy suppresses Th2 responses via modulating TIM1/TIM4 interaction on dendritic cells

  2009cites this paper
• Immunomodulation of allergic immune response during specific immunotherapy

  2009influential citation